Literature DB >> 7028060

Effect of chronic diuretic treatment on the plasma renin-angiotensin-aldosterone system in essential hypertension.

P Lijnen, R Fagard, J Staessen, A Amery.   

Abstract

1 Chronic treatment with a constant dose of hydrochlorothiazide or tienilic acid increases plasma renin activity (PRA) acutely to reach a maximum within the first week. 2 During chronic diuretic therapy from 1 month to 1 year, PRA remained elevated at a rather constant level, though this was somewhat lower than the maximum level reached after 1 week. 3 A significant (P less than 0.01) correlation (r = 0.74) between changes in plasma angiotensin II and renin activity provoked by chronic treatment for 3 months with hydrochlorothiazide and tienilic acid was found. 4 The increase in plasma aldosterone during chronic treatment with hydrochlorothiazide and tienilic acid (1000 mg) is related (r = 0.68; P less than 0.01) to the rise in plasma angiotensin II.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7028060      PMCID: PMC1401821          DOI: 10.1111/j.1365-2125.1981.tb01231.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  14 in total

1.  Dissociation of blood angiotensin II and plasma renin activity during chronic treatment in essential hypertension.

Authors:  M P Sambhi; J D Barrett; P Eggena; C Thananopavarn
Journal:  Clin Sci Mol Med Suppl       Date:  1976-12

2.  Stimulated renin: a screening test for hypertension.

Authors:  L Wallach; I Nyarai; K G Dawson
Journal:  Ann Intern Med       Date:  1975-01       Impact factor: 25.391

3.  Endogenous angiotensin I concentration in human plasma.

Authors:  P J Lijnen; A K Amery; R H Fagard
Journal:  J Lab Clin Med       Date:  1978-09

4.  Vasoconstriction-volume analysis for understanding and treating hypertension: the use of renin and aldosterone profiles.

Authors:  J H Laragh
Journal:  Am J Med       Date:  1973-09       Impact factor: 4.965

5.  Metabolism and blood levels of angiotensin II in normal subjects, renal disease, and essential hypertension.

Authors:  K J Catt; M D Cain; J P Coghlan; P Z Zimmet; E Cran; J B Best
Journal:  Circ Res       Date:  1970-10       Impact factor: 17.367

6.  [Electrolyte balance, plasma renin concentration and reaction of blood pressure in patients with essential hypertension and control subjects during therapy with metolazone, a new diuretic].

Authors:  K Hayduk; G Riegger; D K Krause; W Kaufmann
Journal:  Arzneimittelforschung       Date:  1974-01

7.  Renin-angiotensin-aldosterone system during chronic thiazide therapy of benign hypertension.

Authors:  J J Bourgoignie; F J Catanzaro; H M Perry
Journal:  Circulation       Date:  1968-01       Impact factor: 29.690

8.  Direct radioimmunoassay of plasma aldosterone in normal subjects.

Authors:  P Lijnen; A Amery; R Fagard; P Corvol
Journal:  Clin Chim Acta       Date:  1978-03-15       Impact factor: 3.786

9.  Faster radioimmunoassay of angiotensin I at 37 degrees C.

Authors:  F Fyhrquist; L Puutula
Journal:  Clin Chem       Date:  1978-01       Impact factor: 8.327

10.  Hemodynamic changes during long-term thiazide treatment of essential hypertension in responders and nonresponders.

Authors:  P van Brummelen; A J Man in 't Veld; M A Schalekamp
Journal:  Clin Pharmacol Ther       Date:  1980-03       Impact factor: 6.875

View more
  16 in total

1.  Hormonal effects of the diuretic xipamide in healthy men.

Authors:  P Lijnen; R Fagard; J Staessen; A Amery
Journal:  Cardiovasc Drugs Ther       Date:  1991-08       Impact factor: 3.727

2.  Randomized trial comparing the velocities of the antihypertensive effects on home blood pressure of candesartan and candesartan with hydrochlorothiazide.

Authors:  Miki Hosaka; Hirohito Metoki; Michihiro Satoh; Takayoshi Ohkubo; Kei Asayama; Masahiro Kikuya; Ryusuke Inoue; Taku Obara; Takuo Hirose; Yutaka Imai
Journal:  Hypertens Res       Date:  2015-06-04       Impact factor: 3.872

3.  Cerebral blood flow regulation in end-stage kidney disease.

Authors:  Justin D Sprick; Joe R Nocera; Ihab Hajjar; W Charles O'Neill; James Bailey; Jeanie Park
Journal:  Am J Physiol Renal Physiol       Date:  2020-09-28

4.  Long-term effects of a renin inhibitor versus a thiazide diuretic on arterial stiffness and left ventricular diastolic function in elderly hypertensive patients.

Authors:  Yoshiyuki Okada; Shigeki Shibata; Naoki Fujimoto; Stuart A Best; Benjamin D Levine; Qi Fu
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2017-07-19       Impact factor: 3.619

Review 5.  Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control.

Authors:  Carlos M Ferrario
Journal:  Life Sci       Date:  2009-12-01       Impact factor: 5.037

Review 6.  Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination.

Authors:  Francesca Cagnoni; Christian Achiri Ngu Njwe; Augusto Zaninelli; Alessandra Rossi Ricci; Diletta Daffra; Antonio D'Ospina; Paola Preti; Maurizio Destro
Journal:  Vasc Health Risk Manag       Date:  2010-08-09

Review 7.  Clinical pharmacokinetics and pharmacodynamics of aliskiren.

Authors:  Sujata Vaidyanathan; Venkateswar Jarugula; Hans Armin Dieterich; Dan Howard; William P Dole
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

8.  Chronic renin inhibition lowers blood pressure and reduces upright muscle sympathetic nerve activity in hypertensive seniors.

Authors:  Yoshiyuki Okada; Sara S Jarvis; Stuart A Best; Tiffany B Bivens; Beverley Adams-Huet; Benjamin D Levine; Qi Fu
Journal:  J Physiol       Date:  2013-09-23       Impact factor: 5.182

9.  Plasma atrial natriuretic peptide and the renin-aldosterone system during long-term administration of the diuretic xipamide in man.

Authors:  P Lijnen; P Hespel; R Fagard; J Staessen; W Goossens; W Lissens; A Amery
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

10.  Safety and efficacy of aliskiren/amlodipine/hydrochlorothiazide triple combination in patients with moderate to severe hypertension: a 54-week, open-label study.

Authors:  Alexander V Murray; Wolfgang Koenig; Juan Garcia-Puig; Samir Patel; Alkaz Uddin; Jack Zhang
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-08-28       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.